There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals Inc (RCKT) and Zogenix (ZGNX) with bullish sentiments.
Rocket Pharmaceuticals Inc (RCKT)
William Blair analyst Raju Prasad maintained a Buy rating on Rocket Pharmaceuticals Inc today. The company’s shares closed yesterday at $19.78.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 25.4% and a 67.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Logicbio Therapeutics Inc, and Allogene Therapeutics Inc.
Rocket Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.
See today’s analyst top recommended stocks >>
Zogenix (ZGNX)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix today. The company’s shares closed yesterday at $51.85.
Yang commented:
“We spoke to management – they indicated that they did not believe such studies were necessary based on their interactions with the FDA. The key issue now revolves around whether or not ZGNX will need to complete additional studies (which could take 6 to 9 months). For conservative purposes, we assume additional studies will be required and a delayed product launch. With these assumptions, our PT goes to $58. We would be buyers of the shares on volatility at market open.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.9% and a 47.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Zogenix is a Strong Buy with an average price target of $71.20, a 37.3% upside from current levels. In a report issued on April 5, Northland Securities also maintained a Buy rating on the stock with a $70 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
